Leukemia

Articles

Study results from the Journal of Medical Internet Research indicated that medication adherence by way of reminders on mobile devices for patients with acute lymphoblastic leukemia and their caregivers may have validity. 

Using Mobile Apps May Be Feasible for Promoting Drug Adherence in ALL

Data in The Lancet promoted a tolerable safety profile and future feasibility of UCART19 administration among patients with relapsed and refractory B cell ALL.

Manageable Safety Profile Observed in Phase 1 Studies Examining UCART19 for Pediatric and Adult Patients with B-Cell ALL

Tisagenlecleucel has already received FDA approval and is now available at some treatment centers, thereby imparting significance to results about tocilizumab use in patients at-risk for severe cytokine release syndrome.

Preemptive Tocilizumab Decreases CRS After Tisagenlecleucel Administration in Pediatric B-Cell ALL

Based on recent study results, investigators recommended TBI plus etoposide for patients older than 4 years of age with high-risk ALL undergoing allogeneic hematopoietic stem cell transplantation. 

TBI Plus Etoposide Prior to HSCT Leads to Improved OS, Lower Relapse Risk in High-Risk Pediatric ALL

The addition of the monoclonal antibody blinatumomab to hyper-CVAD could represent a potential option for extending remission times in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia.

Patients with Ph- B-cell ALL May Benefit From Addition of Blinatumomab to Chemotherapy Combo

Videos

Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.

Nicholas J. Short, MD, on the Future of ALL and Possibilities for Transplant in These Patients

Short described the importance of the time point of CR outcomes for patients treated as part of an ALL study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Nicholas Short, MD, on the Surprising Significance of CR Outcomes for Patients With ALL After Frontline Therapy

Short discussed currently available assays for MRD detection, blinatumomab treatment, and other implications from an ALL study presented at the 2020 ASH Annual Meeting.

Nicholas Short, MD Discusses MRD-Detection Assays and Blinatumomab for Patients With ALL

Short summarized the NGS-based MRD findings from his ALL study presented at the 2020 ASH Annual Meeting.

Nicholas Short, MD, on Findings from Study Examining NGS-Based MRD Assessment for Patients with ALL

The allogeneic off-the-shelf CD22-directed T-cell product, UCART22, showed early signs of activity and no evidence of unexpected toxicities for adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

Acute Lymphoblastic Leukemia | Topics